Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26039004 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR | |
| SCHEMBL24129464 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL24129189 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR | |
| SCHEMBL16028047 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL25857288 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR | |
| SCHEMBL15014467 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR | |
| SCHEMBL3038968 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR | |
| SCHEMBL25857292 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL15928087 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2KCNH2CYP2D6TSHRCYP2C19 | |
| SCHEMBL27407439 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2KCNH2KMT2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| WO-2021257828-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2021-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | SMN1; SMN2 3947/4885KCNH2 4588/4885MEN1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.